

**Acronym**

ScreenTB

**Full Title**

Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB

**Programme**

EDCTP2/2<sup>nd</sup> European & Developing Countries Clinical Trials Partnership Programme

**Contract Number**

DRIA2014-311

**Abstract**

Recently, new recommendations regarding screening for active TB have been formulated and these include a focus on high TB prevalence areas, people living with HIV infection and populations with difficult access to efficient TB diagnostic services, such as access to GeneXpert testing. Our proposed project builds on extensive experience gained during EDCTP I, is based on strong and very promising host biomarker data and on in-depth experience with point-of-care (POC) implementation of user-friendly lateral flow assays (LFAs). The proposal addresses the important topic of screening for active TB, which would significantly speed up and streamline diagnostic approaches in resource-limited settings. We have identified a six-marker diagnostic signature for active TB with sensitivity of 89% and specificity of 75%, regardless of HIV status and are proposing to implement testing of this signature through rapid, laboratory-free POC LFAs with the capability to measure multiple markers simultaneously. The proposed LFA device utilizes novel, nano-sized upconverting phosphor (UCP) reporter particles as quantitative read-out with excellent sensitivity and robustness; the UCP label is not hampered by common auto-fluorescence background and does not fade over time. The LFA can be adapted for measurement of markers in finger-prick blood, which will further enhance its POC utility. Our non-interventional trial will recruit 800 people with symptoms suggestive of active TB, regardless of HIV infection status, and across five African countries. UCP-LFA test results will be compared to gold standard tests and established project-specific case definitions. The successful implementation of a sensitive, cost effective screening test with test performance similar to our current biosignature would streamline diagnostic programs in resource-limited settings and could decrease unnecessary referrals for GeneXpert testing by 75%. Additionally, we will continue to build significant African clinical trial capacity by hosting workshops on clinical trial and laboratory procedures during our annual meetings and by supporting the promising early and mid-career African scientists through a mentorship program and by improving South-South and South-North networking.

**Duration**

36 months (01/04/2016 - 31/03/2019)

## **Project Funding**

2.998.834 €

## **Coordinator**

Prof. Gerhard Walzl  
Stellenbosch University  
Faculty of Health Sciences  
Division of Molecular Biology and Human Genetics  
Department of Biomedical Sciences  
Francie van Zijl Drive  
PO Box 19063  
Tygerberg 7505, South Africa  
Tel: +27 21 9389158  
Fax: +27 21 9389476  
Email: gwalzl@sun.ac.za

## **Partners**

- Medical Research Council, The Gambia
- Armauer Hansen Research Institute, Ethiopia
- Makerere University, Uganda
- University of Namibia, Namibia
- Academisch Ziekenhuis Leiden, The Netherlands
- London School of Hygiene and Tropical Medicine, United Kingdom
- European Research and Project Office GmbH, Germany
- LINQ management GmbH, Germany

## **Project Management**

Julia Buech  
LINQ management GmbH  
Phone: +49 6894 92 808 10  
Email: j.buech@linq-management.com

## **Project Website**

[www.screen-tb.eu](http://www.screen-tb.eu)